Renaissance Technologies
PGNX

Renaissance Technologies’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Renaissance Technologies’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-836,789
Closed -$3.88M – 3836
2019
Q1 		$3.88M Buy
836,789
+608,078
+266% +$2.75M ﹤0.01% 1968
2018
Q4 		$961K Buy
+228,711
New +$1.16M ﹤0.01% 2591
2017
Q3 		– Sell
-291,489
Closed -$1.98M – 3456
2017
Q2 		$1.98M Buy
291,489
+48,100
+20% +$355K ﹤0.01% 2268
2017
Q1 		$2.3M Buy
+243,389
New +$2.43M ﹤0.01% 2168
2015
Q1 		– Sell
-210,698
Closed -$1.59M – 3421
2014
Q4 		$1.59M Buy
+210,698
New +$1.26M ﹤0.01% 1921
2013
Q4 		– Sell
-280,100
Closed -$1.41M – 3090
2013
Q3 		$1.41M Buy
280,100
+177,011
+172% +$960K ﹤0.01% 1842
2013
Q2 		$460K Buy
+103,089
New +$463K ﹤0.01% 2263

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies's PGNX Position: Q2 2019 in Review

Renaissance Technologies sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2019, closing a stake of 836,789 shares — an estimated $3.88M sold.

Renaissance Technologies first reported a position in PGNX in Q2 2013 and held it in 7 quarters. The position peaked at $3.88M in Q1 2019. 142 funds tracked by Wall St. Rank hold PGNX as of Q2 2019.

  • Renaissance Technologies reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2019 after selling out during the quarter.
  • Renaissance Technologies sold 836,789 Progenics Pharmaceuticals Inc shares in Q2 2019, an estimated $3.88M.
  • Renaissance Technologies first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 7 quarters.
  • Renaissance Technologies's Progenics Pharmaceuticals Inc position peaked at $3.88M in Q1 2019.
  • 142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2019.

Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.